The US Food and Drug Administration (FDA) has granted approval for two hypertension generics, Lupin’s generic amlodipine/benazepril capsules and labetalol hydrochloride (HCl) injection produced by Sagent.
Lupin’s amlodipine/benazepril capsules are the AB-rated generic equivalent of Novartis’ Lotrel capsules and will be available in 2.5mg/10mg, 5mg/10mg, 5mg/20mg and 10mg/20mg capsules. Commercial shipments have already begun.
Go deeper with GlobalData
Lupin Pharmaceuticals president and CEO Vinita Gupta said that this is a significant approval and it broadens the company’s growing portfolio of cardiovascular medications.
Sagent Pharmaceuticals’ labetalol HCl injection will be available in two vial sizes – 100mg per 20mL and 200mg per 40mL, multi-dose vials.
The labetalol HCl injection is the generic equivalent of Prometheus Laboratories’ Trandate (labetalol HCl) injection. Labetalol HCl injection is an adrenergic receptor-blocking agent that has selective alpha1-adrenergic and nonselective beta-adrenergic receptor blocking actions used to control blood pressure in severe hypertension.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
